From PsychonautWiki
Jump to navigation Jump to search
Summary sheet: MiPT
Chemical Nomenclature
Common names MiPT
Substitutive name N-Methyl-N-isopropyltryptamine
Systematic name N-[2-(1H-indol-3-yl)ethyl]-N-methylpropan-2-amine
Class Membership
Psychoactive class Psychedelic
Chemical class Tryptamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Common 10 - 25 mg
Strong 25 - 75 mg
Heavy 75 - 200 mg
Total 3 - 8 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


N-Methyl-N-isopropyltryptamine (also known as MiPT) is a lesser-known psychedelic substance of the tryptamine class. It is structurally related to DMT, along with other analogs such as DiPT, MPT, and MET.

MiPT was first synthesized and investigated by Alexander Shulgin and described in his book TiHKAL ("Tryptamines I Have Known and Loved"). In the commentary, Shulgin notes that "there is almost a total lack of visual phenomena... no wave-forms, color distortion or object shape changes, and no eyes-closed imagery, unlike most N,N-disubstituted tryptamines."[1]

Subjective effects include hallucinatory states, time distortion, conceptual thinking, euphoria, and ego loss. Its effects are generally described as mild, indistinct, and highly variable between users. In contrast to many related tryptamines, it is able to be taken orally.

Today, MiPT remains relatively uncommon and is either used as a recreational or an entheogenic substance. It has been distributed online as a research chemical. Very little data exists about the pharmacological properties, metabolism, and toxicity of MiPT in humans, and it has little history of human usage.


MiPT, or N-methyl-N-isopropyltryptamine, is a synthetic indole molecule of the tryptamine class. Tryptamines share a core structure that comprises a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. Unlike DMT, which contains two methyl groups, MiPT contains groups of one methyl and one isopropyl carbon chains bound to the terminal amine RN of its tryptamine backbone. MiPT is the methyl analog of DiPT.


Further information: Serotonergic psychedelic

Like with most psychedelic tryptamines, MiPT is thought to act principally as a 5-HT2A partial agonist. The psychedelic effects are believed to come from MiPT's binding efficacy at the 5-HT2A receptors.

However, the role of these interactions and how it results in the psychedelic experience continues to remain elusive.

Subjective effects

The sensory effects of MiPT are said to be similar to those of DiPT but with less intensity at the same dose, and without the same bias towards producing auditory distortions.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Cognitive effects

Auditory effects

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational MiPT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because MiPT is a research chemical with very little history of human usage.

Anecdotal evidence from those who have tried MiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this drug.

As with many psychedelics, the use of MiPT has the potential to bring about long-lasting perceptual and psychological alterations. MiPT, in particular, is known to chronically alter the perception of sound and talking, which may not be suitable for everyone.

Tolerance and addiction potential

MiPT is not habit-forming and the desire to use it can actually decrease with regular consumption. Like with most psychedelics, it is most often thought to be self-regulating.

Tolerance to the effects of MiPT is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). MiPT presents cross-tolerance with all psychedelics, meaning that after the consumption of MiPT all psychedelics will have a reduced effect.

Legal status

Due to its relative obscurity, the possession and sale of MiPT is unscheduled in most countries.

  • Germany: MiPT is controlled under the NpSG (New Psychoactive Substances Act)[2] as of July 18, 2019.[3] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[4]
  • Sweden: Sweden's public health agency suggested classifying MiPT as a hazardous substance, on May 15, 2019.[5]
  • Switzerland: MiPT is not controlled under Buchstabe A, B, C and D. It could be considered legal.[6]
  • United Kingdom: MiPT is a Class A controlled substance in the United Kingdom as a result of the tryptamine catch-all clause.[7]
  • United States: MiPT is unscheduled in the United States.

See also

External links



Question book-new.svg

This article does not cite enough references.

You can help by adding some.

  1. Shulgin, Alexander; Shulgin, Ann (1997). "#47. MIPT". TiHKAL: The Continuation. United States: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252. 
  2. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019. 
  3. "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020. 
  4. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019. 
  5. "Folkhälsomyndigheten föreslår att 20 ämnen klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten [Public Health Agency]. May 15, 2019. 
  6. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  7. "Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved January 7, 2020.